5 years ago

Beckley Psytech Raises £14 Million to Develop Psychedelic Medicines

  • Beckley Psytech, a UK-based psychedelic medicine company, has raised £14 million in equity funding from Noetic Psychedelic Fund LP, Bail Capital, Jim Mellon, and Richard Reed

  • The company will use the investment to develop psychedelic drugs into licensed pharmaceutical medicines for treating psychiatric and neurological diseases

  • Beckley Psytech is developing a pipeline of psychedelic compounds with distinct clinical attributes for mental and neurological diseases that impact millions of people globally

  • The company is founded by Lady Amanda Feilding and CEO Cosmo Feilding Mellen and has appointed an array of esteemed psychiatric and psychedelic experts to its Scientific Advisory Board, including Dr Robin Carhart-Harris from Imperial College London, Prof Matthew Johnson from Johns Hopkins University, and Prof Guy Goodwin from the University of Oxford.

      • ProblemHealthcare

      "Millions of people worldwide suffer from psychiatric and neurological disorders for which current treatment options are inadequate."

      Solution

      "Develop clinically validated psychedelic medicines into licensed pharmaceutical treatments for patients suffering from debilitating psychiatric and neurological diseases."

      Covered on